San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug market in February immediately after revealing promising information from a mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection and in